CLAIMS

1. Use of a composition comprising an effective amount of a rAAV vector including an open reading frame encoding alpha L-iduronidase or iduronate-2-sulfatase, the expression of which in a human prevents, inhibits or treats the one or more neurological symptoms, in the manufacture of a medicament for the prevention, inhibition or treatment of one or more neurological symptoms in a human, having a deficiency in alpha L-iduronidase or a deficiency in iduronate-2-sulfatase, wherein the medicament is to be administered to a cisterna magna of the human and wherein the rAAV is rAAV-9 or rAAVrh10.

2. The use of claim 1 wherein a permeation enhancer is also to be administered to the human.

3. The use of claim 2, wherein the composition comprises the permeation enhancer.

4. The use of claim 2 or claim 3, wherein the permeation enhancer comprises mannitol, sodium glycocholate, sodium taurocholate, sodium deoxycholate, sodium salicylate, sodium caprylate, sodium caprate, sodium lauryl sulfate, polyoxyethylene-9-laurel ether, or EDTA.

5. The use of claim 1, wherein an immune suppressant is to be administered to the human.

6. The use of claim 5, wherein the immune suppressant comprises cyclophosphamide.

7. The use of claim 5, wherein the immune suppressant comprises a glucocorticoid, cytostatic agents including an alkylating agent, an anti-metabolite, a cytotoxic antibiotic, an antibody, or an agent active on immunophilin.

8. The use of any one of claims 5 to 7, wherein the immune suppressant comprises a nitrogen mustard, nitrosourea, platinum compound, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, an anthracycline, mitomycin C, bleomycin, mithramycin, IL-2 receptor (CD25-) or CD3-directed antibodies, anti-IL-2 antibodies, ciclosporin, tacrolimus, sirolimus, IFN-P, IFN-y, an opioid, or tumor necrosis factor-alpha binding agent.

9. The use of any one of claims 5 to 8, wherein the medicament and the immune suppressant are to be co-administered or the immune suppressant is to be administered after the medicament.

10. The use of any one of claims 5 to 9, wherein the immune suppressant is intrathecally or intracerebroventricularly administered.

11. Use of a composition comprising an effective amount of a rAAV vector including an open reading frame encoding alpha L-iduronidase or iduronate-2-sulfatase, the expression of which in the human prevents, inhibits or treats the one or more symptoms associated with a deficiency in alpha L-iduronidase or a deficiency in iduronate-2-sulfatase in a human, in the manufacture of a medicament for the prevention, inhibition or treatment of one or more symptoms associated with a deficiency in alpha L-iduronidase or a deficiency in iduronate-2-sulfatase in a human, wherein the human has been immunotolerized to alpha-L-iduronidase or iduronate-2-sulfatase; wherein the medicament is to be administered to a cisterna magna of the human, and wherein the rAAV is rAAV-9 or rAAVrh10.

12. The use of any one of claims 1 to 11, wherein the human is an immuno-competent adult.

13. The use of any one of claims 1 to 12, wherein the rAAV vector is a rAAV-9 vector.

14. The use of any one of claims 1 to 13, wherein the open reading frame encodes alpha-L-iduronidase.

15. The use of any one of claims 1 to 14, wherein the disease is a deficiency in alpha-L-iduronidase.

16. The use of any one of claims 1 to 15, wherein multiple doses are to be administered.

17. The use of any one of claims 1 to 15, wherein the medicament is to be administered weekly.

18. The use of any one of claims 1 to 17, wherein neurodegeneration is prevented, inhibited or treated by the administration.

19. The use of any one of claims 1 to 10, wherein prior to administration of the medicament, the human is immunotolerized to the alpha L-iduronidase or iduronate-2-sulfatase.

20. The use of any one of claims 1 to 13, wherein the open reading frame encodes iduronate-2-sulfatase.

21. The use of any one of claims 1 to 12, wherein the rAAV vector is rAAVrh10.